Use of infliximab for the treatment of pemphigus vulgaris.
This study is currently recruiting patients. Verified and sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a synthetic antibody used to treat certain
Condition Intervention Phase
Pemphigus Drug: Infliximab Phase II
Drug: Prednisone
Study ID Numbers: DAIT APV01
ClinicalTrials.gov Identifier: NCT00283712
Email this Article
Digg It
del.icio.usRelated Articles
- Infliximab and TB.
- Infliximab and TB.
- Patient's granuloma annulare clears with infliximab.
- Peptimmune begins Phase I trial for pemphigus vulgaris.
- CASE OF THE MONTH.
- Infliximab (Remicade[R]) to treat dermatomyositis and polymyositis.
- Infliximab (Remicade[R]) to treat dermatomyositis and polymyositis.
- Randomized controlled study to evaluate CellCept in the treatment of pemphigus vulgaris.
- Infliximab (Remicade[R]) to treat dermatomyositis and polymyositis.
- Infliximab (Remicade[R]) to treat dermatomyositis and polymyositis.
- Infliximab (remicade) to treat dermatomyositis and polymyositis.
- HLA typing identifies pemphigus risk factors.
- Infliximab (Remicade[R]) to treat dermatomyositis and polymyositis.
- Pemphigus vulgaris.
- Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists.
Patients with infliximab-induced tuberculosis may be at increased risk of a paradoxical response to anti-tuberculous therapy. Carolina Garcia Videl, M.D, of the University of Barcelona (Spain) and her colleagues reported. A retrospective analysis of 284 patients treated with infliximab showed ......
Patients with infliximab-induced tuberculosis may be at increased risk of a paradoxical response to antituberculous therapy, Carolina Garcia Videl, M.D., of the University of Barcelona (Spain) and her colleagues reported. A retrospective analysis of 284 patients treated with infliximab showed ......
LONDON -- Complete clearing of recalcitrant generalized granuloma annulare following three infusions of infliximab was seen in a 66-year-old man, Dr. Antonio Costanzo reported in a poster presentation at the 14th Congress of the European Academy of Dermatology and Venereology, ......
Peptimmune has announced that it has initiated a Phase I clinical trial to test the safety of PI-0824 in patients with pemphigus vulgaris (PV). The study is being undertaken at four sites. PI-0824 is a synthetic injectible peptide being developed ......
BANFF, ALTA. -- Pemphigus vulgaris is rare in childhood, Dr. Jeffrey Callen said in a poster session at the annual meeting of the Society for Pediatric Dermatology. The disease usually occurs between 40 and 60 years of age. Dermatologically, oral ......
This study is currently recruiting patients. Verified and sponsored by National Institutes of Health Clinical Center. This study will examine whether infliximab (Remicade) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect of a ......
This study is currently recruiting patients. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) This study will examine whether infliximab (Remicade[R]) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect ......
Aspreva Pharmaceuticals Corporation is currently working to provide more evidence-based medicines for less common diseases. The company recently announced the initiation of a Phase III trial to evaluate the safety and efficacy of CellCept (mycophenolate mofetil) with corticosteroids to achieve ......
This study is currently recruiting patients. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will examine whether infliximab (Remicade[R]) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect ......
This study is currently recruiting patients. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will examine whether infliximab (Remicade) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect ......
This study is currently recruiting patients. Sponsored by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will examine whether infliximab is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect of ......
ZURICH -- The human leukocyte antigen class II DRB1*0402 allele proved to be the strongest genetic risk factor for pemphigus vulgaris in both whites and IndoAsians in the largest HLA typing study to date conducted in a European population, Dr....
This study is currently recruiting patients. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This study will examine whether infliximab (Remicade) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect ......
A recent study published in the Archives of Dermatology evaluated adjuvant therapy with oral dexamethasone pulse therapy in the treatment of pemphigus vulgaris. (2) This randomized, multi-center, placebo-controlled trial evaluated 20 patients with new pemphigus vulgaris. Patients were randomized to ......
The authors in this study injected littermates of neonatal athymic nude mice with pemphigus vulgaris (PV) to determine whether a cholinergic agonist can abolish PV IgG-induced acantholysis. Previous studies have determined the importance of cholinergic receptors in the pathogenesis of ......